-
-
Finance -
Pharma & Human Health
-
Pharma & Human Health -
Pharma & Human Health
Editor’s Choice
Editor's Choice
LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
Bacterial vaginosis (BV) is one of the most common vaginal conditions affecting women of reproductive age worldwide, with prevalence rates estimated between 15% and 50%. It is a condition characterized by a disruption of the […]
Editor's Choice
Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
Across women’s health, there is growing recognition of the urgent need for antibiotic‑sparing strategies that restore and sustain an optimal vaginal microbiota. Such an ecosystem is typically dominated by Lactobacillus crispatus, a species strongly associated […]
Editor's Choice
Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
A global team of experts has identified a promising new approach to prevent recurrence of bacterial vaginosis (BV), a condition that affects millions of women worldwide. In a phase 1 randomized clinical trial of women […]
In Case you Missed it:
Pharma & Human Health
Engineered gut bacteria therapy emerges as scalable potential alternative to FMT following clinical trial
Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for […]
Pharma & Human Health
Redefining Probiotic Manufacturing Through Advanced Nutrient Solutions
The global probiotics market has experienced sustained and rapid growth over the past decade, driven by increasing consumer awareness of gut health, immunity, and the central role of the microbiome in overall well‑being. Discussions at […]
Pharma & Human Health
Single-Tube Stool Collection for Gut Multi-Omics: Why It Matters for Metagenomics and Metabolomics
Gut microbiome research has changed. Many studies no longer stop at identifying which microbes are present. They are now also looking at what those microbes are doing, often by measuring the metabolites they produce or […]
Pharma & Human Health
Microbiotica Announces Positive Phase 1b Results for Precision Microbiome Co-Therapy in Advanced Melanoma
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial. […]
Finance
Kanvas Biosciences Secures $48M Series A to advance lead immuno-oncology drug
Kanvas Biosciences, a full-stack spatial biology company, today announced it has raised a $48 million Series A funding round co-led by existing investors DCVC and Lions Capital LLC. Additional participating investors include Gates Foundation, ATHOS […]
Pharma & Human Health
Engineered commensals for metabolic modulation of the gut-liver-brain axis
When the liver fails, toxins – such as ammonia – that should be filtered from the blood build up and reach the brain. The result is hepatic encephalopathy (HE), a devastating neurological complication of liver […]
Editor's Choice
LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
Bacterial vaginosis (BV) is one of the most common vaginal conditions affecting women of reproductive age worldwide, with prevalence rates estimated between 15% and 50%. It is a condition characterized by a disruption of the […]
Finance
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for IBS
EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class microbiome therapies for gut health, today announces the completion of a £19m ($25m) financing to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome […]
